Study shows PromarkerD ability to also predict late-stage kidney decline in type-2 diabetes patients

The Company is pleased to announce the results of a study demonstrating the potential ability of the PromarkerD test to predict late-stage renal decline.

PromarkerD is already a proven diagnostic test for diabetic kidney disease, predicting the onset of the condition up to four years in advance. This study, presented overnight at the American Diabetes Association’s 82nd Scientific Sessions, extends the potential use of PromarkerD to predict a further decline in renal function among people who already have kidney disease, broadening the Company’s target market to encompass 32m adults with diabetes in the United States.

ASX Release